Binding of C1q to Galectin-3 Binding Protein on Microvesicles Released by Mononuclear Cells from Patients with Systemic Lupus Erythematosus
Main Article Content
Abstract
Background: Generation of galectin-3 binding protein (G3BP)-expressing microvesicles can be induced in-vitro by Toll-like receptor 9 ligation in mononuclear cells. Microvesicles co-expressing G3BP and double-stranded DNA are associated with active lupus nephritis. However, whether the microvesicular G3BP mainly deposits from circulation or is endogenously derived is unknown. In this study, we aim to delineate the origin of G3BP on in-vitro generated microvesicles by using serum as a source of native G3BP.
Methods: G3BP-expressing microvesicles, generated by stimulation of systemic lupus erythematosus patient-derived mononuclear cells with the Toll-like receptor 9-agonist ODN2395, were incubated with normal human serum, heat-inactivated human serum, recombinant human C1q or human albumin. The expression of G3BP by microvesicles was examined by flow cytometry, and the binding of soluble recombinant human C1q to recombinant human G3BP was investigated by ELISA.
Results: Approximately half of the microvesicles released from mononuclear cells expressed G3BP. Surprisingly, the staining was abrogated by incubation of the microvesicles with normal human serum, while incubation with heat-inactivated human serum did not have a similar effect. Reasoning that C1q might be the heat-labile factor blocking access of our G3BP antibody detection system, we incubated microvesicles with recombinant human C1q, which on average inhibited the detectable proportion of G3BP-bearing microvesicles by 87%. Soluble recombinant human C1q bound to immobilized recombinant human G3BP in a dose-dependent manner.
Conclusion: Our data suggest that soluble C1q binds to G3BP on Toll-like receptor 9-induced microvesicles released from systemic lupus erythematosus patient-derived mononuclear cells. This interaction may exarcerbate inflammation in systemic lupus erythematosus but may also serve as a general mechanism for the appropriate clearance of these potentially pathogenic factors.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Lötvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles; 2014:26913. doi: 10.3402/jev.v3.26913
3. Inal JM, Ansa-Addo EA, Stratton D, et al. Microvesicles in health and disease. Arch Immunol Ther Exp (Warsz); 2012:107-121. doi: 10.1007/s00005-012-0165-2
4. Distler JH, Pisetsky DS, Huber LC, Kalden JR, Gay S, Distler O. Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum; 2005:3337-3348. doi: 10.1002/art.21350
5. Ståhl AL, Johansson K, Mossberg M, Kahn R, Karpman D. Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases. Pediatr Nephrol; 2019:11-30. doi: 10.1007/s00467-017-3816-z
6. Nielsen CT, Østergaard O, Rasmussen NS, Jacobsen S, Heegaard NHH. A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus. Clin Proteomics; 2017:11. doi: 10.1186/s12014-017-9146-0
7. Nielsen CT, Østergaard O, Rekvig OP, Sturfelt G, Jacobsen S, Heegaard NH. Galectin-3 binding protein links circulating microparticles with electron dense glomerular deposits in lupus nephritis. Lupus; 2015:1150-1160. doi: 10.1177/0961203315580146
8. Dieker J, Tel J, Pieterse E, et al. Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis. Arthritis Rheumatol; 2016:462-472. doi: 10.1002/art.39417
9. Nielsen CT, Østergaard O, Stener L, et al. Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis Rheum; 2012:1227-1236. doi: 10.1002/art.34381
10. Østergaard O, Nielsen CT, Iversen LV, et al. Unique protein signature of circulating microparticles in systemic lupus erythematosus. Arthritis Rheum; 2013:2680-2690. doi: 10.1002/art.38065
11. Østergaard O, Nielsen CT, Tanassi JT, Iversen LV, Jacobsen S, Heegaard NHH. Distinct proteome pathology of circulating microparticles in systemic lupus erythematosus. Clin Proteomics; 2017:23. doi: 10.1186/s12014-017-9159-8
12. Ramacciotti E, Hawley AE, Wrobleski SK, et al. Proteomics of microparticles after deep venous thrombosis. Thromb Res; 2010:e269-274. doi: 10.1016/j.thromres.2010.01.019
13. Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT. Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer; 2001:167-172. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1022>3.3.co;2-q
14. Sasaki T, Brakebusch C, Engel J, Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J; 1998:1606-1613. doi: 10.1093/emboj/17.6.1606
15. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem; 1993:14245-14249. doi: 10.1016/S0021-9258(19)85233-X
16. Martínez VG, Moestrup SK, Holmskov U, Mollenhauer J, Lozano F. The conserved scavenger receptor cysteine-rich superfamily in therapy and diagnosis. Pharmacol Rev; 2011:967-1000. doi: 10.1124/pr.111.004523
17. Nielsen CT, Rasmussen NS, Heegaard NH, Jacobsen S. "Kill" the messenger: targeting of cell-derived microparticles in lupus nephritis. Autoimmun Rev; 2016:719-725. doi: 10.1016/j.autrev.2016.03.009
18. Loimaranta V, Hepojoki J, Laaksoaho O, Pulliainen AT. Galectin-3-binding protein: a multitask glycoprotein with innate immunity functions in viral and bacterial infections. J Leukoc Biol; 2018:777-786. doi: 10.1002/JLB.3VMR0118-036R
19. Rasmussen NS, Nielsen CT, Jacobsen S, Nielsen CH. Stimulation of mononuclear cells through Toll-like receptor 9 induces release of microvesicles expressing double-stranded DNA and galectin 3-binding protein in an interferon-α-dependent manner. Front Immunol; 2019:2391. doi: 10.3389/fimmu.2019.02391
20. Rasmussen NS, Nielsen CT, Nielsen CH, Jacobsen S. Microvesicles in active lupus nephritis show Toll-like receptor 9-dependent co-expression of galectin-3 binding protein and double-stranded DNA. Clin Exp Immunol; 2021:64-77. doi: 10.1111/cei.13569
21. Hochberg MC. Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum; 1997:1725. doi: 10.1002/art.1780400928
22. Gray WD, Mitchell AJ, Searles CD. An accurate, precise method for general labeling of extracellular vesicles. MethodsX; 2015:360-367. doi: 10.1016/j.mex.2015.08.002
23. Lozada C, Levin RI, Huie M, et al. Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci U S A; 1995:8378-8382. doi: 10.1073/pnas.92.18.8378
24. Nauta AJ, Trouw LA, Daha MR, et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol; 2002:1726-1736. doi: 10.1002/1521-4141(200206)32;6<1726::AID-IMMU1726>3.0.CO;2-R
25. Botto M, Walport MJ. C1q, autoimmunity and apoptosis. Immunobiology; 2002:395-406. doi: 10.1078/0171-2985-00141
26. Schifferli JA, Steiger G, Hauptmann G, Spaeth PJ, Sjöholm AG. Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization. J Clin Invest; 1985:2127-2133. doi: 10.1172/JCI112217
27. Eggleton P, Tenner AJ, Reid KB. C1q receptors. Clin Exp Immunol; 2000:406-412. doi: 10.1046/J.1365-2249.2000.01218.x
28. Sjöwall C, Olin AI, Skogh T, et al. C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis. Autoimmunity; 2013:205-214. doi: 10.3109/08916934.2013.764992
29. Tan Y, Song D, Wu LH, Yu F, Zhao MH. Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis. BMC Nephrol; 2013:63. doi: 10.1186/1471-2369-14-63
30. Nielsen CH, Rasmussen JM, Voss A, Junker P, Leslie RG. Diminished ability of erythrocytes from patients with systemic lupus erythematosus to limit opsonized immune complex deposition on leukocytes and activation of granulocytes. Arthritis Rheum; 1998:613-622. doi: 10.1002/1529-0131(199804)41:4<613::AID-ART8>3.0.CO;2-A
31. Gasser O, Schifferli JA. Microparticles released by human neutrophils adhere to erythrocytes in the presence of complement. Exp Cell Res; 2005:381-387. doi: 10.1016/j.yexcr.2005.03.011
32. Winberg LK, Rasmussen NS, Nielsen CH, Jacobsen S. Erythrocytes restrict microvesicle-induced production of reactive oxygen species by polymorphonuclear leukocytes. APMIS; 2019:538-542. doi: 10.1111/apm.12954
33. Klickstein LB, Barbashov SF, Liu T, Jack RM, Nicholson-Weller A. Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity; 1997:345-355. doi: 10.1016/s1074-7613(00)80356-8